Related Experiment Videos
[Steroid pulse therapy in rapidly progressive glomerulonephritis].
1Department of Internal Medicine, Kanazawa National Hospital.
Nihon Jinzo Gakkai Shi
|June 1, 1992
Summary
Methylprednisolone pulse therapy effectively treats rapidly progressive glomerulonephritis (RPGN). This treatment reduced creatinine levels and improved kidney function in both acute and subacute RPGN patients.
Area of Science:
- Nephrology
- Immunosuppressive Therapy
Background:
- Rapidly progressive glomerulonephritis (RPGN) is a severe kidney disease.
- Methylprednisolone pulse therapy is a potential treatment for RPGN.
Observation:
- Three patients with RPGN were treated with methylprednisolone pulse therapy (1000 mg x 3).
- Patients were classified into acute and subacute types based on creatinine decline rate.
- Renal biopsies showed significant crescent formation in glomeruli.
Findings:
- In acute RPGN, one course of therapy decreased creatinine from 3.0 to 1.3 mg/dl and transformed cellular crescents.
- In subacute RPGN, initial therapy reduced creatinine and further courses improved levels and cleared crescents.
- Therapy demonstrated efficacy in reducing serum creatinine and improving renal histology.
Implications:
- Methylprednisolone pulse therapy is indicated for RPGN.
- The treatment shows promise in managing RPGN, potentially halting or reversing kidney damage.
- Further research may solidify its role in RPGN management.